-
Caraco Announces Stockholder Approval of Merger Agreement with Sun Pharma and Consummation of the Merger
Tuesday, June 14, 2011 - 12:39pm | 231Caraco Pharmaceutical Laboratories Ltd. (NYSE: CPD) announced that at a special meeting of stockholders held on June 14, 2011, Caraco's stockholders voted to approve and adopt the previously announced merger agreement by and among Sun Pharmaceutical Industries Limited, Sun Pharma Global, Inc., Sun...
-
Dr. Reddy's Chemical Manufacturing Facility at Cuernavaca, Mexico Receives Warning Letter from USFDA
Tuesday, June 14, 2011 - 11:55am | 103Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced today that Industrias Quimicas Falcon de Mexico SA de C.V., a wholly owned subsidiary of Dr. Reddy's Laboratories Limited, has received a four item Warning Letter from the United States Food and Drug Administration. The USFDA inspected Dr. Reddy...
-
CryoPort (OTCBB: CYRX) Adds Veteran Biopharmaceutical Executive to Management Team
Tuesday, June 14, 2011 - 10:09am | 529CryoPort Inc. (OTCBB: CYRX), a provider of technology-driven transport and packaging systems focused on helping companies similar to Life Technologies Corp. (NASDAQ: LIFE) and Pfizer Inc. (NYSE: PFE), recently added veteran biopharmaceutical executive, Mark Engelhart, to its management team as...
-
Abbott Receives FDA Approval for CREON Infant-Specific Dosage for Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Tuesday, June 14, 2011 - 9:31am | 77Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration has approved an infant-specific dose of CREON Delayed-Release Capsules to treat exocrine pancreatic insufficiency due to cystic fibrosis. The CREON 3,000 units of lipase capsule provides the lowest dosage strength in...
-
pSivida and Pfizer Amend Agreement to Focus Solely on Development of Sustained-Release Implant to Deliver Latanoprost
Tuesday, June 14, 2011 - 9:08am | 86Drug delivery company pSivida Corp (NASDAQ: PSDV) today announced it amended and restated its Research and Development Agreement with Pfizer Inc. (NYSE: PFE) to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and...
-
Former CEO of Aetna Appointed to Johnson & Johnson Board
Tuesday, June 14, 2011 - 9:03am | 61Ronald A. Williams, former chairman and chief executive officer of Aetna Inc. (NYSE: AET), has been appointed to the Board of Directors of Johnson & Johnson (NYSE: JNJ). Mr. Williams will serve on the Compensation & Benefits Committee and the Public Policy Advisory Committee of the Board.
-
ULURU Inc. Raises $140,000 in Convertible Debt Offering
Tuesday, June 14, 2011 - 8:01am | 196ULURU Inc. (NYSE: ULU) today announced it has completed a $140,000 convertible debt financing with Kerry P. Gray, the Company's Chairman, President, and Chief Executive Officer. The Company intends to use the funds for general corporate purposes. The convertible notes will bear interest at the...
-
UPDATE: Wedbush Color on Map Pharmaceuticals PT Increase
Tuesday, June 14, 2011 - 7:41am | 107Wedbush, which raised its PT on shares of MAP Pharmaceuticals, Inc. (NASDAQ: MAPP), is providing some color on the stock. “The main concern investors have shared with us is safety since Levadex is orally-inhaled but not targeting a lung disease,” Wedbush writes. “Recall that Exubera (inhaled...
-
Piper Jaffray Reiterates Overweight on Valeant Pharmaceuticals
Tuesday, June 14, 2011 - 7:34am | 109Piper Jaffray is out with its report today on Valeant Pharmaceuticals (NYSE: VRX), reiterating Overweight. In a note to clients, Piper Jaffray writes, "We continue to envision U.S. sales north of $200M by 2014 (VRX will share profits with Glaxo). With a new growth driver for the U.S. neurology...
-
UPDATE: Piper Jaffray Raises PT on Watson Pharmaceuticals to $76
Tuesday, June 14, 2011 - 7:27am | 90Piper Jaffray is out with its report today on Watson Pharmaceuticals (NYSE: WPI), raising its PT from $72 to $76. In a note to clients, Piper Jaffray writes, "With a P/E of only 11x our new 2012 EPS estimate of $5.94 (up from $5.69), and significant potential for double-digit EPS growth beyond...
-
Wedbush Raises PT On MAP Pharmaceuticals To $25
Tuesday, June 14, 2011 - 6:20am | 27Wedbush Securities has raised the price target on MAP Pharmaceuticals (NASDAQ: MAPP) from $24 to $25 and maintains its Outperform rating.
-
Piper Jaffray Raises PT On Watson Pharmaceuticals To $76
Tuesday, June 14, 2011 - 6:08am | 27Piper Jaffray has raised the price target on Watson Pharmaceuticals (NYSE: WPI) from $72 to $76 and maintains its Overweight rating.
-
Build a Wealthy Portfolio with These Economic Moats
Tuesday, June 14, 2011 - 1:33am | 1474Warren Buffett mentions moats all the time in his talks and writings and emphasizes the importance of finding a company with moats. The thing is, I haven't come across anything specific from Buffett where he explains how to distinguish and categorize moats but The Little Book That Builds Wealth...
-
Teva Signs $4 Billion Syndicated Credit Facilities
Monday, June 13, 2011 - 3:29pm | 33Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has entered into Syndicated Credit Facilities totaling $4 billion supporting the $6.8 billion acquisition of Cephalon, Inc.
-
Dollar Strength Dips the Market 06-10-2011
Monday, June 13, 2011 - 3:05pm | 938Cusick's Corner This is one of those moments where one side of the market gets to sit back and think things are fat and happy - dollar up, metals and market down. This is a moment, one to respect, and now the "whys" start to pop up, .i.e. the market is down because of bad data/weak sectors like...